Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
POZN's Cash to Debt is ranked higher than
84% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. POZN: No Debt )
POZN' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Equity to Asset 0.50
POZN's Equity to Asset is ranked higher than
56% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. POZN: 0.50 )
POZN' s 10-Year Equity to Asset Range
Min: 0.36   Max: 0.94
Current: 0.5

0.36
0.94
Interest Coverage No Debt
POZN's Interest Coverage is ranked higher than
86% of the 460 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 88.77 vs. POZN: No Debt )
POZN' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 4.31
M-Score: -6.71
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -162.60
POZN's Operating margin (%) is ranked lower than
55% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.34 vs. POZN: -162.60 )
POZN' s 10-Year Operating margin (%) Range
Min: -477.51   Max: 48.51
Current: -162.6

-477.51
48.51
Net-margin (%) -161.87
POZN's Net-margin (%) is ranked lower than
56% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. POZN: -161.87 )
POZN' s 10-Year Net-margin (%) Range
Min: -472.67   Max: 48.69
Current: -161.87

-472.67
48.69
ROE (%) -93.93
POZN's ROE (%) is ranked lower than
57% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. POZN: -93.93 )
POZN' s 10-Year ROE (%) Range
Min: -618.07   Max: 40.13
Current: -93.93

-618.07
40.13
ROA (%) -47.29
POZN's ROA (%) is ranked lower than
55% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.94 vs. POZN: -47.29 )
POZN' s 10-Year ROA (%) Range
Min: -280.81   Max: 34.83
Current: -47.29

-280.81
34.83
ROC (Joel Greenblatt) (%) -43035.90
POZN's ROC (Joel Greenblatt) (%) is ranked lower than
60% of the 732 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.50 vs. POZN: -43035.90 )
POZN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -43035.9   Max: 40949.51
Current: -43035.9

-43035.9
40949.51
Revenue Growth (%) -46.90
POZN's Revenue Growth (%) is ranked lower than
58% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. POZN: -46.90 )
POZN' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 52.4
Current: -46.9

0
52.4
» POZN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

POZN Guru Trades in Q1 2013

John Rogers 783,580 sh (New)
Jim Simons 165,962 sh (+135.04%)
» More
Q2 2013

POZN Guru Trades in Q2 2013

John Rogers 3,228,236 sh (+311.99%)
Jim Simons 268,444 sh (+61.75%)
» More
Q3 2013

POZN Guru Trades in Q3 2013

John Rogers 4,379,824 sh (+35.67%)
Jim Simons 34,886 sh (-87%)
» More
Q4 2013

POZN Guru Trades in Q4 2013

Jim Simons 250,219 sh (+617.25%)
John Rogers 3,503,586 sh (-20.01%)
» More
» Details

Insider Trades

Latest Guru Trades with POZN



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about POZEN, Inc.

John Rogers Makes 5 Real-Time Increases
John Rogers made five real time increases on June 30. These increases came at the close of the second quarter. [b] Read more...

Ratios

vs
industry
vs
history
P/B 15.00
POZN's P/B is ranked lower than
73% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.84 vs. POZN: 15.00 )
POZN' s 10-Year P/B Range
Min: 1.11   Max: 25.07
Current: 15

1.11
25.07
P/S 26.36
POZN's P/S is ranked lower than
83% of the 722 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. POZN: 26.36 )
POZN' s 10-Year P/S Range
Min: 1.4   Max: 255.57
Current: 26.36

1.4
255.57
Shiller P/E 200.84
POZN's Shiller P/E is ranked lower than
71% of the 362 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.59 vs. POZN: 200.84 )
POZN' s 10-Year Shiller P/E Range
Min: 22.94   Max: 263.33
Current: 200.84

22.94
263.33

Valuation & Return

vs
industry
vs
history
Price/Net Cash 17.40
POZN's Price/Net Cash is ranked lower than
59% of the 214 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.10 vs. POZN: 17.40 )
POZN' s 10-Year Price/Net Cash Range
Min: 1.14   Max: 25.36
Current: 17.4

1.14
25.36
Price/Net Current Asset Value 16.11
POZN's Price/Net Current Asset Value is ranked lower than
65% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.80 vs. POZN: 16.11 )
POZN' s 10-Year Price/Net Current Asset Value Range
Min: 1.14   Max: 22.65
Current: 16.11

1.14
22.65
Price/Tangible Book 15.00
POZN's Price/Tangible Book is ranked lower than
79% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.10 vs. POZN: 15.00 )
POZN' s 10-Year Price/Tangible Book Range
Min: 1.12   Max: 20.72
Current: 15

1.12
20.72
Price/DCF (Projected) 7.77
POZN's Price/DCF (Projected) is ranked lower than
67% of the 346 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. POZN: 7.77 )
POZN' s 10-Year Price/DCF (Projected) Range
Min: 0.53   Max: 33.33
Current: 7.77

0.53
33.33
Price/Median PS Value 3.45
POZN's Price/Median PS Value is ranked lower than
76% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. POZN: 3.45 )
POZN' s 10-Year Price/Median PS Value Range
Min: 0.19   Max: 10.3
Current: 3.45

0.19
10.3
Earnings Yield (Greenblatt) 27.40
POZN's Earnings Yield (Greenblatt) is ranked higher than
96% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. POZN: 27.40 )
POZN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 1372.1
Current: 27.4

0.1
1372.1
Forward Rate of Return (Yacktman) 0.92
POZN's Forward Rate of Return (Yacktman) is ranked higher than
71% of the 532 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. POZN: 0.92 )
POZN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -9   Max: 5.4
Current: 0.92

-9
5.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:PZ6.Germany
POZEN Inc., is incorporated in the state of Delaware on September 25, 1996. It operates as a pharmaceutical company focused on developing products which could provide improved efficacy, safety or patient convenience in the treatment of acute and chronic pain and pain related conditions. The Company has developed Treximet in collaboration with GlaxoSmithKline. Treximet is the brand name for the product combining sumatriptan 85 mg, formulated with RT Technology and naproxen sodium 500 mg in a single tablet designed for the acute treatment of migraine. Treximet incorporates its MT 400 technology, which refers to its proprietary combinations of a triptan (5-HT1B/1D agonist) and a non-steroidal anti-inflammatory drug, or NSAID. Under its MT 400 technology, it seeks to develop product candidates that provide acute migraine therapy by combining the activity of two drugs that act by different mechanisms to reduce the pain and associated symptoms of migraine. It is developing product candidates that combine a type of acid inhibitor, a proton pump inhibitor, with an NSAID. These product candidates plan to provide management of pain and inflammations associated with conditions such as osteoarthritis, and are intended to have fewer gastrointestinal complications compared to an NSAID taken alone. It has also developed VIMOVO with AstraZeneca AB, or AstraZeneca. VIMOVO (formerly referred to as PN 400) is the brand name for a proprietary fixed dose combination of the PPI esomeprazole magnesium with the NSAID naproxen in a single tablet. On April 30, 2010, the FDA approved VIMOVO for the relief of the signs and symptoms of osteoarthritis ("OA"), rheumatoid arthritis ("RA") and ankylosing spondylitis ("AS") and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. The competition for VIMOVO comes from the oral anti-arthritic market, or more specifically the traditional non-selective NSAIDs (such as naproxen and diclofenac), traditional NSAID/gastroprotective agent combination products or combination product packages (such as Arthrotec and Prevacid NapraPACTM ) and the only remaining COX-2 inhibitor, Celebrex. Therapeutic product candidates for human use are subject to rigorous preclinical and clinical testing and other requirements of the Federal Food, Drug and Cosmetic Act, or FFDCA, implemented by the FDA, as well as similar statutory and regulatory requirements of foreign countries.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide